Frequently Asked Questions

See answers to both provider and patient questions

Top Questions From Patients

For patient outcomes and success stories, please contact the SurForce® Healthcare Provider nearest you.
The easiest way to get started is by filling out the contact questionnaire found here. We can identify the nearest SurForce® Providers in your area. A Provider will contact you shortly to address any of your questions or concerns. Surgenex distributes its products exclusively to verified medical facilities.
All tissue is donated from mothers after Caesarean section births, and screened extensively by AATB-accredited tissue recovery agencies before being sent to our facility.
Our bodies naturally degenerate over time. The regenerative processes that were once vibrant and energetic in our youth become slower and impeded as we age.
Your Provider may or may not recommend post-treatment rehabilitation. This decision will depend heavily upon the injured area and its pathology/etiology, as well as your current physical health status. Patients should work with their Healthcare Provider to determine if rehab will be necessary and/or beneficial.
Depending on the etiology, pathology, and severity of the chief complaint, each patient will be unique. Healthcare Providers can gather subjective and objective information such as patient history, orthopaedic examinations, diagnostic imaging, and lab results to assess and determine the patient’s needs. Based on these findings, Healthcare Providers can specify an appropriate treatment plan. Costs associated with specific procedures may depend on these variables. For specifics, contacting the nearest Provider for a consultation is recommended.
Depending on the region, or if there are multiple locations needing an injection, the treatment procedure can be administered during a standard office visit. Specific times may vary depending on factors inherent to the complications of the patient’s needs. The application of the treatment is non-surgical, and requires no pre-treatment preparation time.
Research shows that amniotic membrane and cord tissues contain extracellular matrices including growth factors, anti-fibrotics, anti-microbials, are immune-evasive, and have anti-inflammatory properties. Please peruse our Research section here for research articles related to the naturally occurring properties of amniotic membrane and cord tissues.

Top Questions From Providers

We hold ourselves to a higher standard to perform above and beyond the minimum requirements in the industry, ensuring best practices and superior product outcomes. All allografts have been tested for relevant communicable diseases in accordance with the required FDA standards for tissue donation. Additionally, our donor serology test panel is the most extensive in the industry, testing for several potential pathogens that could be missed by less extensive testing observed in competitive industry products. SURGENEX® conducts a 14-day bacterial/fungal test performed by a third-party lab, to confirm our products are free of bacterial and fungal contaminants. These two safety barriers verify that our products are the cleanest and safest tissue allograft products on the market.
All products including SurForce®, Surcord®, and SurFactor® are injectables categorized as Human Cells, Tissues and Cellular and Tissue-Based Products (HCT/P’s) under Section 361. Currently, the FDA regulates all biological regenerative products under this Section. Moreover, under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and 42 CFR part 493, all contracted laboratories performing human specimen tests are certified and meet the requirements as determined by the Centers for Medicare and Medicaid Services (CMS). SURGENEX® is current in the FDA Establishment Registration and Listing of Human Cells, Tissues and Cellular and Tissue-Based Products (HCT/P).
Donor eligibility requirements are set forth and regulated by the FDA to ensure the Donor of the Placental tissue for transplantation is free of specific infectious and communicable diseases. Donor recoveries meet and adhere to the regulations requisite to HCT/P recovery. Screening and testing of the tissue donor is verified through laboratory serology test panels. Once all criteria are satisfied, the donor placental tissue is deemed qualified for processing and transplantation.
The FDA requires HCT/P products under section 361 to be traceable in the event of an adverse reaction. Lot tracking is utilized as a course of action for documenting the management and storage of a specimen from donor to collector to the final transplant destination, and the review and reporting of the final results by a Healthcare Provider.
SURGENEX®, LLC accepts no returns of any allograft product. Although SURGENEX®, LLC has taken great measures to ensure the safety of our allograft product, current technologies cannot preclude the transmission of certain diseases known or unknown, therefore, SURGENEX®, LLC can make no claims concerning the biological properties and safety of allograft tissue. All tissues have been collected, processed, screened, tested, stored, and distributed in compliance with all current FDA regulations concerning HCT/Ps.
Autograft is defined as a graft of tissue from one point to another of the same individual's body, simply, a host to host implantation of tissue. Whereas an Allograft is a tissue graft from a donor of the same species as the recipient but not genetically identical, or simply, a donor to recipient transplantation of tissue.
Depending on the product, distribution of SURGENEX® products are either cryopreserved and shipped in shipping containers utilizing dry ice to maintain critical low temperatures or processed to be shelf-stable and are shipped with priority shipping to our providers.